Overall, identification of TIAM1OE in human BPH cohorts via bioinformatic and protein analyses was followed by complementary studies of genetic TIAM1 knockdown/overexpression and pharmacological-based RAC1 inhibition in experimental in vitro BPH models to identify a new role for the TIAM1/RAC1 axis in human BPH. This evidence concerns the gene RAC1 and benign prostatic hyperplasia.